Monoclonal antibody 35B5 as well as preparation method and application thereof
Through the development of monoclonal antibody 35B5, the problem of poor neutralization effect against the RBD domain of the new coronavirus spike protein in the existing technology has been solved, and effective inhibition of multiple new coronavirus strains, including original strains and mutant strains, has been achieved , significantly reducing virus titers and inflammatory responses.
Patent Information
- Application Number
- CN202110940804.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2021-08-17
- Publication Date
- 2021-09-14
- Estimated Expiration
- 2041-08-17
AI Technical Summary
There is a lack of effective antibodies against the RBD domain of the spike protein of the new coronavirus in the existing technology. Especially when faced with multiple mutant strains, the neutralizing effect is poor, and deficiencies in preparation and application lead to limited therapeutic effects.
A monoclonal antibody 35B5 and its antigen-binding fragment were developed. By specifically binding to specific amino acid residues of the spike protein, blocking its binding to the ACE2 receptor, it has high affinity and can effectively neutralize a variety of new coronavirus strains. , including original strains and mutant strains.
Antibody 35B5 significantly reduces the viral titer of SARS-CoV-2, reduces the expression of inflammatory factors, and improves inflammatory infiltration. Its binding structure with RBD avoids mutation sites, ensuring effective inhibition of multiple mutant strains.
